Press release
Acute myocardial infarction Market Analysis: Epidemiology Insights, Therapies, Companies, by DelveInsight | Idorsia Pharmaceuticals, Viatris, Recardio, AstraZeneca, Faraday Pharmaceuticals, CeleCor Th
Acute myocardial infarction Market Analysis
Emerging therapies for acute myocardial infarction (AMI), including LODOCO (colchicine), TNKase (tenecteplase), Dutogliptin, Selatogrel, and others, are anticipated to drive growth in the AMI market over the coming years.
DelveInsight has introduced a new report titled "Acute Myocardial Infarction - Market Insights, Epidemiology, and Market Forecast-2034", offering a comprehensive analysis of the condition, its historical and projected epidemiology, and market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Discover about the Acute myocardial infarction market report @ https://www.delveinsight.com/report-store/acute-myocardial-infarction-ami-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Some of the key facts of the Acute myocardial infarction Market Report:
*
The acute myocardial infarction (AMI) market across the 7MM was valued at approximately USD 1.6 billion in 2023 and is projected to grow at a strong CAGR through the forecast period. The United States dominated the market, accounting for nearly 75% of the total share.
*
In 2023, there were an estimated 1.47 million incident cases of AMI in the 7MM, with the US reporting the highest burden at around 822,800 new cases, a figure expected to rise by 2034. Within subtypes, NSTEMI cases outnumbered STEMI, with about 607,300 NSTEMI cases reported in the US alone. In Japan, incident cases included roughly 45,700 STEMI and 34,500 NSTEMI, while in the EU4 and the UK, there were around 930,900 male and 537,500 female cases of AMI in 2023.
*
Recent regulatory milestones are shaping the treatment landscape. The FDA approved AGEPHA Pharma's LODOCO for patients with residual inflammatory risk, marking the first therapy to directly target inflammatory pathways driving cardiovascular events. Additionally, novel platelet antagonists such as Zalunfiban and Selatogrel are showing promise with subcutaneous administration at first medical contact for STEMI patients. In April 2024, the FDA also granted Breakthrough Device Designation to PMcardio's STEMI AI ECG Model, an AI-based platform designed to analyze 12-lead ECGs for rapid detection of STEMI and other cardiac conditions.
*
The AMI market outlook is expected to evolve further, supported by advances in diagnostics, increased awareness, and rising healthcare expenditure. Key industry players-including Idorsia Pharmaceuticals, Viatris, Recardio, Amgen, Faraday Pharmaceuticals, Novo Nordisk, Bristol Myers Squibb, Johnson & Johnson Innovative Medicine, CeleCor Therapeutics, Kancera, CellProthera, BioCardia, AstraZeneca, Arrowhead Pharmaceuticals, and others-are actively progressing clinical candidates.
*
Notable pipeline therapies include LODOCO (colchicine), TNKase (tenecteplase), Dutogliptin, Selatogrel, and additional investigational agents poised to transform the treatment landscape between 2024 and 2034.
Acute myocardial infarction Overview
Acute Myocardial Infarction (AMI), commonly referred to as a heart attack, is a serious condition that occurs when blood flow to a section of the heart muscle is suddenly obstructed. This usually happens due to a blockage in one of the coronary arteries, which are responsible for delivering oxygen and nutrients to the heart.
AMI is a frequent outcome of cardiovascular disease (CVD), particularly in older adults, and is associated with a high risk of mortality, complications, and significant healthcare costs. While several effective post-infarction treatments exist, current guidelines recommend lifelong preventive therapy-typically including beta-blockers, ACE inhibitors or angiotensin II receptor blockers, acetylsalicylic acid, and statins-unless contraindications are present.
Acute myocardial infarction Market Outlook
A number of leading pharmaceutical companies are actively developing therapies for acute myocardial infarction (AMI), including Idorsia Pharmaceuticals, Viatris, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Amgen, Arrowhead Pharmaceuticals, Faraday Pharmaceuticals, Novo Nordisk, Bristol Myers Squibb, Johnson & Johnson Innovative Medicine, Recardio, CeleCor Therapeutics, Kancera, CellProthera, BioCardia, Mesoblast, and others. Detailed insights into market size by therapy and country are outlined below.
Within the 7MM, the United States accounted for the largest share of the AMI market in 2023, while Spain represented the smallest, with a market size of about USD 25 million.
Among pipeline therapies anticipated to enter the market during the forecast period, Ziltivekimab is expected to generate the highest revenue by 2034.
Discover how the Acute myocardial infarction market is rising in the coming years @ https://www.delveinsight.com/sample-request/acute-myocardial-infarction-ami-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Acute myocardial infarction marketed drugs
*
LODOCO (colchicine): AGEPHA Pharma
*
TNKase (tenecteplase): Genentech
Acute myocardial infarction Emerging Drugs
*
Dutogliptin: Recardio
*
Selatogrel: Idorsia Pharmaceuticals and Viatris
Scope of the Acute myocardial infarction Market Report
*
Study Period: 2020-2034
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Acute myocardial infarction Companies: Idorsia Pharmaceuticals, Viatris, Recardio, AstraZeneca, Faraday Pharmaceuticals, CeleCor Therapeutics, Novo Nordisk, Bristol Myers Squibb, Johnson & Johnson Innovative Medicine, CellProthera, BioCardia, Kancera, Amgen, Arrowhead Pharmaceuticals, and others
*
Key Acute myocardial infarction Therapies: LODOCO (colchicine), TNKase (tenecteplase), Dutogliptin, Selatogrel, and others
*
Acute myocardial infarction Therapeutic Assessment: Acute myocardial infarction current marketed and Acute myocardial infarction emerging therapies
*
Acute myocardial infarction Market Dynamics: Acute myocardial infarction market drivers and Acute myocardial infarction market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Acute myocardial infarction Unmet Needs, KOL's views, Analyst's views, Acute myocardial infarction Market Access and Reimbursement
To know what's more in our Acute myocardial infarction report, visit https://www.delveinsight.com/report-store/acute-myocardial-infarction-ami-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Key benefits of the Acute myocardial infarction Market Report:
*
Acute myocardial infarction market report covers a descriptive overview and comprehensive insight of the Acute myocardial infarction Epidemiology and Acute myocardial infarction market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
*
The Acute myocardial infarction market report provides insights into the current and emerging therapies.
*
The Acute myocardial infarction market report provides a global historical and forecasted market covering drug outreach in 7MM.
*
The Acute myocardial infarction market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Acute myocardial infarction market.
Got queries? Click here to know more about the Acute myocardial infarction market Landscape [https://www.delveinsight.com/sample-request/acute-myocardial-infarction-ami-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Acute myocardial infarction Patient Share (%) Overview at a Glance
5. Acute myocardial infarction Market Overview at a Glance
6. Acute myocardial infarction Disease Background and Overview
7. Acute myocardial infarction Epidemiology and Patient Population
8. Country-Specific Patient Population of Acute myocardial infarction
9. Acute myocardial infarction Current Treatment and Medical Practices
10. Unmet Needs
11. Acute myocardial infarction Emerging Therapies
12. Acute myocardial infarction Market Outlook
13. Country-Wise Acute myocardial infarction Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Acute myocardial infarction Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Click here to read more about Acute myocardial infarction Market Outlook 2034 [https://www.delveinsight.com/report-store/acute-myocardial-infarction-ami-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Related Reports:
Acute myocardial infarction Pipeline Insights, DelveInsight
"Acute myocardial infarction Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Acute myocardial infarction market. A detailed picture of the Acute myocardial infarction pipeline landscape is provided, which includes the disease overview and Acute myocardial infarction treatment guidelines.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=acute-myocardial-infarction-market-analysis-epidemiology-insights-therapies-companies-by-delveinsight-idorsia-pharmaceuticals-viatris-recardio-astrazeneca-faraday-pharmaceuticals-celecor-th]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Acute myocardial infarction Market Analysis: Epidemiology Insights, Therapies, Companies, by DelveInsight | Idorsia Pharmaceuticals, Viatris, Recardio, AstraZeneca, Faraday Pharmaceuticals, CeleCor Th here
News-ID: 4190097 • Views: …
More Releases from ABNewswire
Understanding Magnetic Switches: Types, Working Principles, and Applications
A magnetic switch is a versatile electrical device that operates by responding to magnetic fields. From Hall Effect to reed switches, explore their functions, types, and diverse applications.
What is a Magnetic Switch?
A magnetic switch is an electrical device that operates by responding to the presence of a magnetic field. It functions by closing or opening its contacts based on the strength of the magnetic field. Specifically, the switch remains closed…
Innovating embedded downlight technology: Leading the global trend of intelligen …
The strong rise of China's manufacturing industry has profoundly reshaped the technological landscape and development trajectory of embedded downlights. With its unparalleled industrial chain advantages, continuous technological innovation, and significant cost-effectiveness, Chinese enterprises have risen from participants in the global lighting industry to undisputed leaders. This transformation goes far beyond the huge production scale; it lies in the thorough innovation of the core technical content and application boundaries of embedded…
North China Electric Power University Foreign Aid Training Program Visits Yiyuan …
On July 23, 2025, the Electrical Industry Training Program of North China Electric Power University's Foreign Aid Project visited Yiyuan Technology for an exchange visit. The purpose was to gain in-depth insights into the company's innovations in renewable energy technology promotion and application [https://www.yiyen.com/about/], and to build bridges connecting university-enterprise cooperation with foreign aid initiatives.
Image: https://ecdn6.globalso.com/upload/p/1108/image_other/2025-07/scene-1.jpg
Image: https://ecdn6.globalso.com/upload/p/1108/image_other/2025-07/scene-3.jpg
Upon arrival, the delegation received a warm welcome from company leadership and the reception…
Pure Sine Wave Low Frequency Inverter Charger
Pure sine wave low frequency inverter [https://www.yiypower.com/ap-mini-600w-1500w-120v-low-frequency-pure-sine-wave-inverter-charger-product/] is widely used and suitable for a variety of scenarios. In terms of home backup power, it can provide reliable power during power outages, ensuring that essential appliances such as refrigerators, air conditioners and medical equipment continue to operate . For solar power generation systems, Inverter charger [https://www.yiypower.com/ap-mini-600w-1500w-120v-low-frequency-pure-sine-wave-inverter-charger-product/] can converter DC Power from Battery, which charged by solar panels, into clean alternating current…
More Releases for Acute
Acute Lymphoblastic Leukemia Therapeutics Market Size, Acute Lymphoblastic Leuke …
Acute Lymphoblastic Leukemia Therapeutics Market Dynamics are clarified by an in-depth review of facts on current and emerging trends. To understand a resource, the paper uses Porter's five forces to examine the importance of numerous qualities such as understanding of suppliers and customers, dangers provided by various agents, competitive strength, and promising new businesses. precious. Furthermore, the study covers numerous firms' Acute Lymphoblastic Leukemia Therapeutics research data, benefit, gross margin,…
Acute Conjunctivitis Treatment Market: The Future Insights Of Global Acute Conju …
Acute Conjunctivitis Treatment Market
Acute Conjunctivitis Treatment Market, or pink eye, is an irritation or inflammation of the conjunctiva that covers the white part of the eyeball. It can be caused by allergies or a bacterial or viral infection. Acute Conjunctivitis Treatment Market can be highly communicable and can be spread easily by the contact with secretions of eye from the infected person. Conjunctivitis often resolves on its own, but…
Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H …
ReportsWorldwide has announced the addition of a new report title Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports.
GlobalData's clinical trial report, “Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Renal Failure (ARF) (Acute Kidney Injury) clinical trials scenario. This report provides top line data relating to…
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical T …
ReportsWorldwide has announced the addition of a new report title Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports.
GlobalData's clinical trial report, “Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) clinical trials scenario. This report provides top line data relating to…
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Tri …
ReportsWorldwide has announced the addition of a new report title Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports.
GlobalData's clinical trial report, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) clinical trials scenario. This report provides top line data relating to…
H2 2016 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeut …
Albany, New York, January 03, 2017: A recent forecast report focusing on the Acute Myelocytic Leukemia Market has been added to the wide portfolio of Market Research Hub (MRH). It is entitled as, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2016” which has been equipped by in-depth market examination with inputs from the industry experts. It covers the current market scenario and also its future growth…
